Summary Text

SUMMARY: First diagnosed with myeloma October 2011. Recruited onto clinical trial Myeloma X11 (Lenalidomide) at Bristol Oncology and Haematology Centre. First High Dose Therapy and Stem Cell Transplant (HDT&SCT) in July 2012. On maintenance until June 2017. June 2018 recruited onto Myeloma XII trial (Ixazomib). December 2018 Second HDT&SCT. On maintenance until February 2020. August 2020 Commenced treatment involving Daratumumab. April 2021 relapsed. June 2021 recruited onto Cartitude 4 clinical trial and infused with CAR-T cells in October 2021. My own immune system is now fighting the cancer . I am exceedingly fortunate.


Monday, 12 August 2019

Maintenance #4

From the title, readers will realise that I have good news.  After last week's less-than-good news, today I again attended clinic and after one scare, the news was good. 

To remind you, when I attend clinic I receive a blood test.  This is analysed in the unit whilst samples are also sent to the hospital laboratory.  The unit's system reported my platelet count at 67 and thus too low to return to treatment.  Fortunately the laboratory result, which came through during a rather extended wait to see the consultant, was much more welcome at 82 and thus qualifying me to continue.  Last week's paraprotein result also suggested a plateau so I was prescribed the necessary medications for maintenance cycle number 4. Wow.







It seems to have been so much effort and anxiety for just three capsules of Izazomib and the two prophylactic medications.

But it's truly worth it !












KBO

Keep well

Stephen